CJC-1295 No DAC + Ipamorelin 10mg

Quickstart Highlights

CJC1295 NO DAC + Ipamorelin 10mg dosage protocol supports enhanced growth hormone release and recovery through daily subcutaneous injections.

Typical total daily dose ranges from 300–600 mcg for most protocols
5-days-on, 2-days-off schedule is common to prevent receptor desensitization
Gradual titration approach to optimize tolerability and results
Reconstitute to a practical concentration for accurate syringe measurements
Store lyophilized in the freezer; keep reconstituted vials refrigerated

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Advanced / Aggressive Approach (2 mL = 5,000 mcg/mL)

Week	Daily Dosage (mcg)	Units (approx.)
Weeks 1–4	600 mcg (once daily)	~12 units
Weeks 5–8	800 mcg (once daily)	~16 units
Weeks 9–12	1,000 mcg (once daily)	~20 units
Weeks 13–16 (Optional)	1,200 mcg (once daily)	~24 units

Reconstitute with 3 mL of bacteriostatic water to achieve an approximate 3,333 mcg/mL concentration. Note that 300 mcg requires about 9 units, which is slightly below 10. If higher precision is needed, consider using a 50-unit or 30-unit syringe.
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly along the vial wall to minimize foam.
Gently swirl—avoid vigorous shaking.
Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
For those requiring higher daily doses (600–1,200 mcg), reconstitute with 2 mL to achieve 5,000 mcg/mL. This helps keep injection units comfortably above 10.
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
Inject slowly to prevent excess foaming or bubbling.
Gently roll/swirl the vial—avoid vigorous shaking.

Supplies Needed

Ensure you have these on hand for an 8–16 week cycle.

Peptide Vials:• 8 wks ≈ 2 vials• 12 wks ≈ 3 vials• 16 wks ≈ 4 vials(More if planning higher doses or extended use)
Insulin Syringes:• 8 wks ≈ 40 syringes (daily use, 5 days on/2 days off)• 12 wks ≈ 60 syringes• 16 wks ≈ 80 syringes
Bacteriostatic Water: 1× 30 ml (or more as needed)
Alcohol Swabs: 1 box

Protocol Overview

A concise summary of this daily subcutaneous injection regimen.

Goal: Enhance growth hormone release and support recovery
Schedule: Typically 5 days on, 2 days off (e.g., Monday–Friday)
Dose Range: 300–600 mcg daily for most researchers, with advanced users reaching 1,000+ mcg
Reconstitution: Aim for 2–3 mL for easy measuring on insulin syringes
Storage: Lyophilized vials in the freezer; reconstituted vials in the refrigerator

Dosing Protocol

Suggested once-daily injection approach for consistent GH pulses.

Daily Dose: Start at ~300 mcg; gradually increase as tolerated
Frequency: Daily injections, 5 on/2 off per week
Cycle Length: 8–16 weeks, followed by a rest period to maintain receptor sensitivity
Advanced Doses: May exceed 600 mcg daily based on research goals
Timing: Best on an empty stomach; morning or before bed

Storage Instructions

Proper storage ensures peptide integrity.

Lyophilized: Store in a freezer (−20°C) for maximum shelf life
Reconstituted: Keep at 2–8°C (refrigerated)
Use within 30 days of mixing; avoid exposing reconstituted solutions to heat/light
Avoid frequent freeze-thaw cycles

Important Notes

Practical tips to enhance safety and efficacy.

Rotate injection sites and always use new, sterile syringes.
For best results, inject on an empty stomach and wait ~30 minutes before eating.
Monitor for adverse reactions; discontinue use if serious issues arise.
Track progress weekly; adjust dosage and protocol duration as research suggests.

How This Works

CJC1295 NO DAC combined with Ipamorelin synergistically boosts growth hormone release.

Potential Benefits & Side Effects

Research suggests improvements in recovery, body composition, and sleep quality.

Enhanced muscle recovery and repair
Improved sleep patterns and overall restfulness
Possible side effects include mild water retention, headaches, or joint discomfort
Less common: injection-site irritation or transient flushing

Injection Technique

General subcutaneous guidance from clinical best-practice resources[7][8].

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[7]. Open source
Do not aspirate for subcutaneous injections; inject slowly and steadily[8]. Open source
Rotate sites systematically (abdomen, thighs, upper arms) to avoid local tissue changes[11]. Open source
Withdraw the needle at the same angle; dispose immediately in a sharps container.

Lifestyle Factors

Complement your protocol with healthy habits for optimal outcomes.

Adopt a balanced, protein-rich diet to support muscle and tissue repair
Incorporate regular exercise, focusing on both strength and cardiovascular health
Prioritize stress management and quality sleep

Recommended Source

We recommend Prime Lab Peptides for high-purity CJC-1295 + GHRP-2 (10 mg Blend).

High-purity, third-party-tested lots with batch COAs.
Consistent, ISO-aligned handling and documentation.
Reliable fulfillment to maintain cold-chain integrity.
Shop at Prime Lab Peptides

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

Reference-derived details for CJC-1295 No DAC + Ipamorelin 10mg.

CJC-1295 no DAC & Ipamorelin (10mg Blend Vial) Open source
PubMed — Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults View Source Open source
PubMed — Once-daily CJC-1295 normalizes growth in GHRH knockout mouse View Source Open source
PubMed — Ipamorelin, the first selective growth hormone secretagogue View Source Open source
PMC — Beyond the androgen receptor: GH secretagogues in body composition management View Source Open source
PubMed — Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers View Source Open source
PubMed — Ipamorelin GH pulse kinetics and timing studies View Source Open source
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) View Source Open source
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections View Source Open source
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) View Source Open source
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route View Source Open source
Frontiers in Endocrinology — Growth hormone secretagogues: history and clinical applications View Source Open source
Endocrine Reviews — Ghrelin and growth hormone secretagogues: physiology and applications View Source Open source
Prime Lab Peptides — CJC-1295 NO DAC + Ipamorelin (10 mg Blend) product page View Source Open source